The already approved anti-Covid 19 vaccines have brought billions of euros to the pharmaceutical groups that produce them, starting with the alliance between the American Pfizer and the German BioNTech, which published its financial results on Monday.

This summary concerns private groups who communicate on their results.

It does not include Russian - Sputnik V - and Chinese vaccine projects developed by public institutions.

Pfizer and BioNTech, the big winners

The American giant and the German biotech, associated in the development of an anti-Covid 19 vaccine, were the first in the Western world to announce positive results and to benefit from an authorization in the European Union and in the United States .

And they take advantage of this advantage.

The vaccine brought in more Pfizer than any competitor: 10.8 billion dollars (about 9.2 billion euros) in revenue in the first half of 2021, the period from which it began to collect most of the sales of this treatment.

And the American group continues to raise its forecasts for 2021. The latest news, it intends to draw 33.5 billion dollars from the sales of its vaccine this year.

For its part, BioNTech recorded sales of 7.3 billion euros in the first half of the year.

Unlike Pfizer, which is developing many treatments, the Covid 19 vaccine is its only product for sale and this figure therefore reflects the performance specific to this treatment.

For all of 2021, BioNTech estimates that its sales of anti-Covid 19 vaccines will represent 15.9 billion euros.

Moderna well placed

The American start-up Moderna has, like Pfizer / BioNTech, developed a messenger RNA vaccine which was among the first approved in the Western world.

In the first half of the year, Moderna, which like BioNTech only counts its anti-Covid 19 vaccine as a product in circulation, garnered $ 5.9 billion in sales, or about five billion euros.

For the whole of 2021, Moderna anticipates $ 20 billion in revenue from its vaccine.

AstraZeneca and Johnson & Johnson far behind

The Anglo-Swedish AstraZeneca and the American Johnson & Johnson, via its Belgian subsidiary Janssen, have also had their vaccines approved in the EU, but later.

They are based on a viral vector.

AstraZeneca's is not even approved in the United States, although it plays an important role in other countries such as India.

Above all, these two groups have promised to sell their vaccines without making a profit during the pandemic.

Marketing prices are therefore much lower than those of Pfizer / BioNTech and Moderna.

And the amounts collected are affected.

AstraZeneca announced $ 1.17 billion (one billion euros) in revenue from its vaccine in the first half of the year.

Johnson & Johnson reported $ 264 million (€ 225 million) for theirs, later approved.

For the year as a whole, Johnson & Johnson plans to sell $ 2.5 billion worth of its vaccine, as AstraZeneca did not give a detailed forecast.

Health

Health pass: Why its control in places open to the public is far from infallible

Society

Fires in Europe: EU steps up its aid, sending planes and firefighters

  • Pfizer-BioNTech

  • Anti-covid vaccine

  • Vaccination

  • Coronavirus

  • Covid 19

  • Society